创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction to CDX model

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-26 14:13
  • Views:

(Summary description)InnoModels Biotechnology is a company dedicated to biotechnology innovation, and its unique CDX model is advancing the field of medicine. based on advanced homology modeling technology, the CDX model provides a brand new paradigm for medical research and drug development, and sets a new benchmark for solving clinical challenges and improving the efficiency of drug discovery and development

InnoModels: Introduction to CDX model

(Summary description)InnoModels Biotechnology is a company dedicated to biotechnology innovation, and its unique CDX model is advancing the field of medicine. based on advanced homology modeling technology, the CDX model provides a brand new paradigm for medical research and drug development, and sets a new benchmark for solving clinical challenges and improving the efficiency of drug discovery and development

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-26 14:13
  • Views:
Information

InnoModels Biotechnology is a company dedicated to biotechnology innovation, and its unique CDX model is advancing the field of medicine. based on advanced homology modeling technology, the CDX model provides a brand new paradigm for medical research and drug development, and sets a new benchmark for solving clinical challenges and improving the efficiency of drug discovery and development.
1. Unique features of CDX model
The CDX model is a human cell model based on homology modeling technology, which is capable of simulating human physiological and pathological processes, providing a highly predictable and reliable experimental platform. Compared with traditional animal models, CDX models have higher biosimilarity and better predictability, greatly accelerating the process of new drug development and disease research.
2. Application of CDX model in drug discovery and development
CDX model plays an important role in drug development. By utilizing CDX models for drug screening and evaluation, researchers are able to identify potential drug candidates more quickly and assess their efficacy and safety, thereby shortening the drug discovery cycle and reducing development costs. This efficient drug screening platform provides strong support for the development of safer and more effective drugs.

 


3. Application of CDX model in disease research
CDX modeling also shows great potential in the field of disease research. Using CDX models, researchers can more accurately simulate the physiological and pathological processes of many diseases, and thus study the pathogenesis and progression of diseases in depth. This provides important support for the development of new therapeutic methods and personalized medicine, and is expected to provide more effective treatment options for patients.
4. Future prospects of CDX model
With the continuous development and improvement of homology modeling technology, CDX model will play an increasingly important role in the field of medicine. In the future, CDX models are expected to become a mainstream platform for medical research and drug development, making greater contributions to improving global health and promoting medical progress.

The CDX model of InnoModels Biotechnology, with its unique advantages based on homology modeling technology, brings new opportunities and challenges for medical research and drug development, and is expected to become an important driving force in the future medical field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司